Research Topics
Genomes and Genes | Giovanni MartinelliSummaryAffiliation: University of Bologna Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistanceIlaria Iacobucci
Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Blood 112:3847-55. 2008..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...- New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemiaGiovanni Martinelli
Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Expert Rev Hematol 2:297-303. 2009..New therapeutic approaches are now available, such as dasatinib, nilotinib and bosutinib, and we highlight those that may be applicable to the treatment of adult BCR-ABL1-positive ALL... - Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patientsI Iacobucci
Department of Institute of Hematology and Medical Oncology, L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna 9 40138, Italy
Leukemia 24:66-73. 2010..In conclusion, BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability... - IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli
Molecular Biology Unit, Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
J Clin Oncol 27:5202-7. 2009.... - New targets for Ph+ leukaemia therapyGiovanni Martinelli
Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Best Pract Res Clin Haematol 22:445-54. 2009..In this review, we highlight the most promising drugs for the treatment of adult BCR-ABL-positive leukaemias... 
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnibGiovanni Martinelli
Institute of Hematology and Medical Oncology, University of Bologna, 40138 Bologna, Italy
Clin Adv Hematol Oncol 6:303-10. 2008..Early results from studies combining tipifarnib with imatinib or etoposide in CML and AML have been promising and warrant further evaluation in larger clinical trials...- ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on ChrSimona Soverini
, University of Bologna, Via Massarenti 9-40138 Bologna, Italy
J Clin Oncol 23:4100-9. 2005.... - Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini
Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
Haematologica 92:401-4. 2007..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317... - Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
J Clin Oncol 26:106-11. 2008..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial... - Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical managementGiovanni Martinelli
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
Hematol Oncol 24:196-204. 2006..We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors... - Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti
Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
Blood 120:761-7. 2012..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy... - mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL proteinManuela Mancini
Dipartimento di Ematologia e Scienze Oncologiche Lorenzo e Ariosto Seràgnoli, University of Bologna, Italy
Leuk Res 34:641-8. 2010.... - RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemiaManuela Mancini
Dipartimento di Ematologia e Scienze Oncologiche Lorenzo e Ariosto Seràgnoli, University of Bologna Medical School, Bologna, Italy
J Cell Biochem 109:320-8. 2010..RAD 001 cytotoxicity on cells not expressing the BCR-ABL fusion gene or its p210 protein tyrosine kinase (TK) activity suggests that the inhibition of normal hematopoiesis may represent a drug side effect... - Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci
, University of Bologna, Bologna, Italy
Clin Cancer Res 12:3037-42. 2006..0005 and as a 3-log reduction from median baseline value) already at the time of first achieving a CCgR have significantly longer cytogenetic remission durations than those without this magnitude of molecular response (P < 0.05)... - Imatinib mesylate in the treatment of hematologic malignanciesPier Paolo Piccaluga
Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
Expert Opin Biol Ther 7:1597-611. 2007..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases... - Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti
Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
J Clin Oncol 28:2748-54. 2010..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient... - Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute LeukeIlaria Iacobucci
Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Blood 114:2159-67. 2009.... - Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini
, University of Bologna, Bologna, Italy
Clin Cancer Res 12:7374-9. 2006.... - Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to ImatinibSimona Soverini
, University of Bologna, Bologna, Italy
Clin Chem 50:1205-13. 2004..It may therefore potentially be a valuable tool for regular, large-scale testing of patients undergoing Imatinib treatment... - Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatmentIlaria Iacobucci
, University of Bologna, Bologna, Italy
J Clin Oncol 24:454-9. 2006..Long-term follow-up results continue to improve in terms of rates and durability of the complete cytogenetic response, major or complete molecular response, and progression-free and overall survival... - Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti
Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
Blood 113:3428-34. 2009..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926... - Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571Lucia Mazzacurati
, University of Bologna, Medical School, Bologna, Italy
Hematol J 5:168-77. 2004..In CML, they might further enhance the proliferative advantage and genomic instability of clonal myeloid progenitors featuring a class of poor prognosis patients eventually resistant to STI571... - First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patientsPier Paolo Piccaluga
Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
Leuk Res 28:987-90. 2004..Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients... - Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcriptsGiovanni Martinelli
Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
Haematologica 88:1221-8. 2003..Other genes that have been implicated at the rearrangement breakpoint are GR6 and RPN1 (both on 3q21). The aim of this study was to investigate the expression of the EVI1 fusion genes in AML patients with 3q21q26 syndrome... - Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani
Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
Blood 104:4245-51. 2004..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies... - Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini
Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
Blood 114:2168-71. 2009.... - Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisGiulia Marzocchi
Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
Blood 117:6793-800. 2011..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926... - Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remissionMichele Malagola
, University of Bologna, Italy
Haematologica 89:ECR25. 2004 - Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemiaMatilde Y Follo
Department of Human Anatomical Sciences, Cellular Signalling Laboratory, University of Bologna, Bologna, Italy
J Clin Oncol 27:782-90. 2009..To evaluate the association between the presence of phosphoinositide-phospholipase C beta1 (PI-PLCbeta1) mono-allelic deletion with the clinical outcome of myelodysplastic syndromes (MDS) patients... 
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
Haematologica 95:1415-9. 2010..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...- Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantationSimona Soverini
, University of Bologna, Via Massarenti 9-40138 Bologna, Italy
Blood 102:1588-94. 2003..055). We concluded that cyclin D1 overexpression is closely associated with 11q abnormalities and identifies a subset of MM patients who are more likely to have prolonged duration of remission and EFS following autologous transplantation... - Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemiaPier Paolo Piccaluga
Institute of Hematology and Medical Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Cancer 110:1178-86. 2007..It also has demonstrated promising efficacy in Ph+ ALL but is still being evaluated in phase 2 trials. In this article, the authors reviewed current knowledge on novel tyrosine-kinase inhibitors in adult Ph+ ALL patients... - Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini
Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
Leuk Res 35:1527-9. 2011..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse... - The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani
Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
Haematologica 92:1173-9. 2007..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate... - Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinibRoberto M Lemoli
Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
Blood 114:5191-200. 2009..Moreover, leukemic CD34(-) cells survived exposure to BCR-ABL inhibitors in vivo. Thus, we identified a novel CD34(-) leukemic stem cell subset in CML with peculiar molecular and functional characteristics... - Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri
Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Haematologica 93:1792-6. 2008..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients... - Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Clin Cancer Res 15:1059-63. 2009..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib... - Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaGianantonio Rosti
, University of Bologna, Italy
Blood 103:2284-90. 2004..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet... - Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemiaMichela Palmisano
Institute of Hematology and Medical Oncology L e A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Hematology 13:1-12. 2008.... - Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
Haematologica 92:101-5. 2007..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients... - Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALLSimona Soverini
, University of Bologna, Italy
Lancet Oncol 8:273-4. 2007 - Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini
Department of Haematology Oncology, L e A Serígnoli, University of Bologna, Bologna, Italy
Oncologist 16:868-76. 2011..Here, we discuss the pros and cons of using this approach in TKI selection... - Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGabriele Gugliotta
Department of Hematology and Oncology Seràgnoli, University of Bologna S Orsola Malpighi Hospital, Bologna, Italy
Blood 117:5591-9. 2011..These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www.clinicaltrials.gov as #NCT00514488 and #NCT00510926... - PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylationWilliam L Blalock
Cell Signalling Laboratory, Department of Human Anatomical Sciences, University of Bologna, Bologna, Italy
J Cell Physiol 221:232-41. 2009.... - Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLCMichele Bianchini
, University of Bologna, Via Massarenti No. 9, 40138 Bologna, Italy
Clin Chem 49:1642-50. 2003.... - Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri
Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 93:770-4. 2008..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance... - Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri
Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Haematologica 94:1758-61. 2009..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited... - Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606Manuela Mancini
Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, University of Bologna Medical School, Via Massarenti 9, 40138 Bologna, Italy
Leuk Res 31:979-87. 2007..The putative roles of growth factor (namely IL-3) autocrine loop in BCR-ABL-expressing progenitor progression towards a drug-resistant phenotype are discussed... - Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocationPier Paolo Piccaluga
Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Leuk Lymphoma 47:469-72. 2006.... - Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantationPier Paolo Piccaluga
Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
Leuk Lymphoma 45:731-3. 2004..In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL... - Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II StudyPier Paolo Piccaluga
Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
Haematologica 92:1721-2. 2007..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild... - CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patientsIlaria Iacobucci
Department of Hematology and Oncological Sciences L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Italy
Clin Cancer Res 17:7413-23. 2011..The 9p21 locus, encoding three important tumor suppressors (p16/CDKN2A, p14/ARF, and p15/CDKN2B), is a major target of inactivation in the pathogenesis of many human tumors... - Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndromeGiovanni Martinelli
, University of Bologna, Italy
Haematologica 89:236-7. 2004 - New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli
Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 90:534-41. 2005..This review highlights the development of new TKI as specific molecularly targeted therapy and as the principal mechanisms for overcoming imatinib resistance... - The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri
Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Haematologica 94:205-12. 2009..The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available... - Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani
Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
Blood 113:4497-504. 2009..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488... - The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working PartyIlaria Iacobucci
Molecular Biology Unit, Department of Hematology Oncology Seràgnoli, University of Bologna, Via Massarenti 9, Bologna, Italy
Haematologica 95:1683-90. 2010..So far the occurrence of PAX5 alterations and their clinical correlation have not been investigated in adults with BCR-ABL1-positive acute lymphoblastic leukemia... - Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderlyPier Paolo Piccaluga
, S. Orsola-Malpighi Hospital, University of Bologna, Italy
Haematologica 88:ECR37. 2003 - Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDSMatilde Y Follo
Cellular Signalling Laboratory, Department of Human Anatomical Sciences, University of Bologna, Via Irnerio 48, Bologna, Italy
Proc Natl Acad Sci U S A 106:16811-6. 2009.... - Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti
Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
Leuk Lymphoma 51:583-91. 2010..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria... - Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusionPier Paolo Piccaluga
, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Br J Haematol 134:356. 2006 - Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable stateSilvia Buonamici
, University of Bologna, Italy
Blood 99:443-9. 2002..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML... - Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisSimona Soverini
Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
Haematologica 96:552-7. 2011..We aimed to assess: (i) in how many patients BCR-ABL kinase domain mutations are already detectable at relatively low levels at the time of diagnosis, and (ii) whether mutation detection correlates with subsequent response to therapy... - The cytogenetic response as a surrogate marker of survivalGianantonio Rosti
, Bologna, Italy
Semin Hematol 40:56-61. 2003..Low-risk patients survive longer than non-low-risk patients given the same CgR. Preliminary results from studies with imatinib are superior and CgR remains an important surrogate marker of survival in the imatinib era... - Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni
Department of Hematology Oncology, L and A Seragnoli, University of Bologna and S Orsola Malpighi University Hospital, Bologna, Italy
Blood 114:4939-43. 2009..I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926... - Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemiaGianantonio Rosti
L and A Seràgnoli Institute of Hematology and Medical Oncology, St Orsola Malpighi Hospital, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 88:256-9. 2003.... - Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literaturePier Paolo Piccaluga
, S. Orsola-Malpighi Hospital, University of Bologna, Italy
Haematologica 88:ECR28. 2003 - Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology oneGiovanni Martinelli
Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
Haematologica 87:688-94; discussion 694. 2002..We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others... - Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemiaPier Paolo Piccaluga
Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
Expert Opin Biol Ther 6:1011-22. 2006..In addition, preliminary experiences with novel tyrosine kinase inhibitors in imatinib-resistant Ph+ ALL are discussed... - Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocationGiovanni Martinelli
Molecular Biology Unit, , University of Bologna, Via Massarenti, 9 - 40138 Bologna, Italy
Haematologica 87:EIM08. 2002 - Novel FLT3 point mutation in acute myeloid leukaemiaPier Paolo Piccaluga
, University of Bologna, S Orsola-Malpighi Hospital, Italy
Lancet Oncol 4:604. 2003 - c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cellsAntonio Porro
Department of Biology, University of Bologna, Bologna, Italy
Mol Cancer Res 9:1054-66. 2011.... - A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemiaMichele Baccarani
L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
Blood 99:1527-35. 2002.... - Advances in the treatment for haematological malignanciesPier Paolo Piccaluga
Institute of Hematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
Expert Opin Pharmacother 7:721-32. 2006..Although these novel therapies are beginning to fulfil their promise, continued research efforts are needed to determine the optimal role of these strategies in haemato-oncology... - Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti
Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
Blood 114:4933-8. 2009..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052... - Imatinib mesylate for the treatment of chronic myeloid leukemiaSimona Soverini
Department of Hematology and Oncological Sciences Lorenzo e Ariosto Seràgnoli University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
Expert Rev Anticancer Ther 8:853-64. 2008..Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients... - Interferon-alfa for chronic myeloid leukemiaMichele Baccarani
, University of Bologna and S.Orsola Hospital, Bologna, Italy
Semin Hematol 40:22-33. 2003.... - Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathwayRoberta Bortul
Dipartimento di Morfologia Umana Normale, , Trieste, Italy
Br J Haematol 129:677-86. 2005..Overall, our results indicate that deguelin might be used in the future for increasing sensitivity to therapeutic treatments of leukaemia cells with an active PI3K/Akt signalling network... - Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemiaSimona Soverini
J Clin Oncol 24:e51-2. 2006 - Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patientsMichele Malagola
Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
Br J Haematol 136:87-95. 2007..In this setting of patients, large prospective randomised studies should be planned... - FLT3 inhibition as tailored therapy for acute myeloid leukemiaGiovanni Martinelli
Haematologica 88:4-8. 2003 - Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findingsGiovanni Martinelli
Haematologica 87:554-5. 2002 - Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'AduMarco Vignetti
Department of Cellular Biotechnologies and Hematology, La Sapienza University, Via Benevento 6, 00161 Rome, Italy
Blood 109:3676-8. 2007.... - Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual diseaseGiuseppe Visani
Haematologica 88:ELT15. 2003 - Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic
Department of Medical and Molecular Genetics, Guy s Hospital, King s College London, UK
Blood 109:4635-40. 2007.... - Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes
Institute of Medical and Veterinary Science, Adelaide, Australia
Blood 108:28-37. 2006..We recognize that our recommendations are provisional and will require revision as new evidence emerges... - First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapySerena Merante
J Clin Oncol 24:e6-7. 2006 - Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95Russell L Basser
CSL Ltd, 45 Poplar Rd, Parkville, VIC 3052, Australia
J Clin Oncol 24:370-8. 2006.... - Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patientsDomenico Russo
Unit of Blood Diseases and Cell Therapy, Brescia University, Brescia, Italy
Br J Haematol 131:172-9. 2005..Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients... - PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatmentErnesto Vigna
Unità Operativa di Ematologia Medicine, Cosenza, Italy
Cancer Chemother Pharmacol 61:713-6. 2008..We herein report a case of F/P-positive CEL with retro-orbital localization, who was successfully treated with imatinib... - Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann
Medizinische Klinik II, Johann Wolfgang Goethe Universitat, Frankfurt, Germany
Blood 110:2309-15. 2007..Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015... - Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?Michele Malagola
Blood 105:904; author reply 905. 2005 - Targeted therapy and the T315I mutation in Philadelphia-positive leukemiasSimona Soverini
Haematologica 92:437-9. 2007 - The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patientsPier Paolo Piccaluga
Haematologica 89:1269-71. 2004..000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio <2 after 4 weeks of treatment had significantly better RFS (10.5 vs 4 months) (p=0.004)... - No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?Giuseppe Visani
Department of Hematology, H San Salvatore, Pesaro, Italy
Leuk Lymphoma 45:1361-4. 2004.... - Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser
Department of Hematology, Centre Hospitalier Universitaire, Lille, France
Blood 110:54-8. 2007..Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing... - Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemiaPier Paolo Piccaluga
Eur J Haematol 72:302-3. 2004 - Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treatDaniele Laszlo
Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
Eur J Haematol 72:264-7. 2004.... - Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likelyGiovanni Martinelli
Haematologica 89:495-7. 2004..We now update the molecular follow-up of our patients, also presenting the therapeutic management of these patients... - May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?Leonardo Potenza
Leuk Res 31:269-71. 2007 - NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemiaMichela Palmisano
Haematologica 92:1268-9. 2007..They are associated with a wide spectrum of morphologic subtypes of AML, normal karyotype and FLT3 mutations. The high frequency of NPM1 mutations might provide a suitable marker for monitoring residual disease of AML...